197 related articles for article (PubMed ID: 9723300)
1. Improvement in correlation between oral dose of cyclosporine and cyclosporinemia after substitution of conventional cyclosporine by Neoral cyclosporine in 296 liver transplant patients.
Bilbao I; Parrilla P; Rimola A; Figueras J; Fabrega E; Gomez M; De Vicente E; Margarit C
Transplant Proc; 1998 Aug; 30(5):1833-7. PubMed ID: 9723300
[No Abstract] [Full Text] [Related]
2. Neoral-based immunosuppression in living-related donor liver transplantation.
Liu PP; Chen CL; Chen YS; Wang CC; Chiang YC; Goto S; Cheng YF; Huang TL; Eng HL; Cheung HK; Jawan B
Transplant Proc; 1998 Nov; 30(7):3550-1. PubMed ID: 9838554
[No Abstract] [Full Text] [Related]
3. Conversion from Sandimmune to Neoral in stable liver graft recipients.
Pollard SG; Lodge JP
Transplant Proc; 1996 Aug; 28(4):2244-6. PubMed ID: 8769213
[No Abstract] [Full Text] [Related]
4. Safety of conversion from cyclosporine Sandimmune to cyclosporine Neoral in stable liver transplant patients.
Baruch Y; Assy N; Kramsky R; Enat R
Transplant Proc; 1998 Aug; 30(5):1852-3. PubMed ID: 9723306
[No Abstract] [Full Text] [Related]
5. Conversion from the conventional cyclosporine formulation (Sandimmune) to a new oral microemulsion (Neoral) in stable liver transplant patients.
Dibo-Cohen JM; Conort O; Conti F; Bernard D; Hazebroucq G; Calmus Y
Transplant Proc; 1998 Aug; 30(5):1857. PubMed ID: 9723309
[No Abstract] [Full Text] [Related]
6. Improvement of correlation between oral dose of cyclosporine and cyclosporinemia after substitution of cyclosporine standard presentation by cyclosporine microemulsion one, in 1345 patients with kidney transplantation. Spanish Sandimmune Neoral Conversion Group.
Gentil Govantes MA; Gómez Ullate P; Errasti P; Fernández Fresnedo G; Capdevila L; Sanz Guajardo A; Cubero JJ
Transplant Proc; 1998 Aug; 30(5):1658-9. PubMed ID: 9723231
[No Abstract] [Full Text] [Related]
7. Reduced acute rejection after liver transplantation with Neoral-based double immunosuppression.
Reggiani P; Rossi G; Latham L; Caccamo L; Gatti S; Maggi U; Melada E; Paone G; Doglia M; Vannelli A; Fassati LR
Transplant Proc; 1998 Aug; 30(5):1855-6. PubMed ID: 9723308
[No Abstract] [Full Text] [Related]
8. Increased dosage requirement and rejection after Neoral conversion in pediatric liver transplant patients.
Cao S; Cox KL; Berquist W; So S; Concepcion W; Monge H; Esquivel CO
Transplant Proc; 1998 Dec; 30(8):4322-4. PubMed ID: 9865373
[No Abstract] [Full Text] [Related]
9. Renal function in primary liver transplant recipients receiving neoral (cyclosporine) versus prograf (tacrolimus).
Van Buren D; Payne J; Geevarghese S; MacDonell R; Chapman W; Wright JK; Helderman JH; Richie R; Pinson CW
Transplant Proc; 1998 Jun; 30(4):1401-2. PubMed ID: 9636566
[TBL] [Abstract][Full Text] [Related]
10. Conversion from conventional Sandimmun to Neoral therapy in stable renal transplant recipients.
Løkkegaard H; Asmundsson P; Clausen P; Dieperink H; Hansen JM; Heaf J; Jensen SB; Kornerup HJ; Madsen S; Pedersen EB; Poulsen JV; Rasmussen K
Transplant Proc; 1996 Aug; 28(4):2199-201. PubMed ID: 8769199
[No Abstract] [Full Text] [Related]
11. Cyclosporine peak levels provide a better correlation with the area-under-the-curve than trough levels in liver transplant patients treated with neoral.
Cantarovich M; Barkun J; Besner JG; Metrakos P; Alpert E; Deschénes M; Aalamian Z; Tchervenkov JI
Transplant Proc; 1998 Jun; 30(4):1462-3. PubMed ID: 9636593
[No Abstract] [Full Text] [Related]
12. Neoral as the initial immunosuppressant in liver transplantation; conversion from Sandimmune to Neoral in stable patients.
Kizilisik AT; al-Sebayel M; Ramirez CB
Transplant Proc; 1998 Nov; 30(7):3537-8. PubMed ID: 9838549
[No Abstract] [Full Text] [Related]
13. Neoral versus Sandimmun: clinical impact and modification of immunosuppressive therapy in cardiac transplantation.
Maccherini M; Bernazzali S; Diciolla F; Giunti G; Bizzarri F; Lisi GF; Davoli G; Biagioli B; Giomarelli PP; Simeone F; Caciorgna M; Marchetti L; Pula G; Sani G; Toscano M
Transplant Proc; 1998 Aug; 30(5):1904-5. PubMed ID: 9723327
[No Abstract] [Full Text] [Related]
14. Impact of Sandimmune, Neoral, and Prograf on rejection incidence and renal function in primary liver transplant recipients.
Van Buren D; Payne J; Geevarghese S; MacDonell R; Chapman W; Wright JK; Helderman JH; Richie R; Pinson CW
Transplant Proc; 1998 Aug; 30(5):1830-2. PubMed ID: 9723299
[TBL] [Abstract][Full Text] [Related]
15. Conversion from Sandimmune to Neoral in renal transplant recipients: two-year experience.
Wilczek HE; Akesson P; Warholm C
Transplant Proc; 1998 Aug; 30(5):1753-5. PubMed ID: 9723267
[No Abstract] [Full Text] [Related]
16. Conversion from standard cyclosporine to low-dose cyclosporine and azathioprine therapy as treatment for cyclosporine-related complications in liver transplant patients.
Perkins JD; Sterioff S; Wiesner RH; Offord KP; Rakela J; Dickson ER; Krom RA
Transplant Proc; 1987 Feb; 19(1 Pt 3):2434-6. PubMed ID: 3274533
[No Abstract] [Full Text] [Related]
17. Clinical safety and tolerability of microemulsion cyclosporine in stable renal transplant patients.
Gracida C; Melchor JL
Transplant Proc; 1996 Dec; 28(6):3379. PubMed ID: 8962318
[No Abstract] [Full Text] [Related]
18. Neoral versus Sandimmune in kidney transplantation.
Tisone G; Orlando G; Mercadante E; Vennarecci G; Pisani F; Buonomo O; Negrini S; Casciani CU
Transplant Proc; 1998 Aug; 30(5):1749-50. PubMed ID: 9723265
[No Abstract] [Full Text] [Related]
19. Safety and tolerability of Sandimmun Neoral vs Sandimmun in de novo renal transplant patients after 24 months' treatment. German Neoral Study Group.
Buchholz B; Korn A
Transplant Proc; 1996 Aug; 28(4):2187-8. PubMed ID: 8769195
[No Abstract] [Full Text] [Related]
20. Anasarca and hypertrophic cardiomyopathy in a liver transplant patient on FK506: relieved after a switch to Neoral.
Baruch Y; Weitzman E; Markiewicz W; Eisenman A; Eid A; Enat R
Transplant Proc; 1996 Aug; 28(4):2250-1. PubMed ID: 8769215
[No Abstract] [Full Text] [Related]
[Next] [New Search]
